Navigation Links
Genmab Announces Results for the First Nine Months of 2008
Date:10/29/2008

Summary: Genmab Reports Results for the Nine Month Period Ended September

30, 2008

COPENHAGEN, Denmark, October 29 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the nine-month period ended September 30, 2008. During this period, Genmab reported the following results:

Genmab's revenues were DKK 667 million (USD 128 million) for the nine month period ended September 30, 2008. In the same period of 2007, Genmab recognized revenues of DKK 356 million (USD 68 million).

An operating loss of DKK 508 million (USD 97 million). This compares to an operating loss of DKK 309 million (USD 59 million) reported for the corresponding period of 2007. The larger operating loss was driven by the increased level of pre-clinical and clinical activities associated with the advancement of our product pipeline.

Net financial income for the nine month period ended September 30, 2008 reflected a net loss of DKK 18 million (USD 4 million), compared to a net income of DKK 48 million (USD 9 million) in the same period of 2007. The net financial income reflects a combination of interest income and fair market value adjustments on our portfolio of marketable securities and unrealized foreign exchange adjustments. Our net financial income was negatively impacted by the continued international financial credit crisis.

A net loss of DKK 526 million (USD 101 million) compared to a net loss of DKK 261 million (USD 50 million) for the same period in 2007. The net loss per share was DKK 11.81 (USD 2.26) for the first nine months of 2008 compared to DKK 5.97 (USD 1.14) in the first nine months of 2007.

Genmab ended the nine month period with cash and marketable securities of DKK 2.1 billion (USD 402 million), which is a decrease of DKK 1.6 billion (USD 306 million) from the end of 2007. The decrease primarily arises from the DKK 1.2 billion (USD 240 million at the date of acquisition) acquisiti
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Reaches Milestone in Ofatumumab Collaboration
2. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
3. Genmab A/S - Changes Board/Management/Auditors
4. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
5. Genmab Announces 2008 First Quarter Results
6. Passing of Genmab A/S Annual General Meeting
7. Genmab A/S - Notice to Convene Annual General Meeting
8. Genmabs 2007 Annual Report
9. Genmab Announces Year End 2007 Financial Results
10. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
11. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... One,Medical, Inc. ("China Sky One Medical" or "the Company") ... producing external use,over-the-counter drugs in the People,s Republic of ... list its common stock on the,NASDAQ Global Market., ... NASDAQ Global Market on,September 15, 2008, and that the ...
... HILLS, Mass., Sept. 2 Joseph F. Finn, ... Inc. ("Spherics") for,the benefit of creditors, announced today ... a sealed bid auction on October 10,2008., ... of a first and,second line treatment for Parkinson,s ...
... SUNNYVALE, Calif., Sept. 2 Accuray,Incorporated (Nasdaq: ARAY ... host an Investor and Analyst Meeting in Boston, Mass. ... a.m. PDT). This meeting will,coincide with the 50th Annual ... (ASTRO)., A live webcast of the presentation will ...
Cached Biology Technology:China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 3Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery 2Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
(Date:6/24/2015)... This report provides market analysis of the ... It contains an analysis of the drivers, challenges, and ... from the short, medium, and long term perspective landscapes. ... and technology trends that currently, prevail in the market. ... to efficiently manage the increasing marine traffic and increasing ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Tactical,Products Inc. (Pink Sheets: PDGT.PK), a leading provider ... military as well as to,the corrections, law enforcement ... the company the largest distributor of a unique ... detector models in,the United States. In addition an ...
... Ghent, Belgium VIB researchers at Ghent University have ... offshoots in plants, and how it works. Root offshoots ... Plants draw the necessary nutrients from the soil through ... well-branched root system, plants must form offshoots of their ...
... YORK, Oct. 23, 2008 -- Hypnosis can induce "synesthetic" ... of another within an average brain, according to ... the premiere publication of the Association for Psychological ... synesthesia, contrary to popular belief, do not necessarily have ...
Cached Biology News:Paradigm Tactical Products to be Largest Distributor of Metal/Radiation Detection Wands in United States 2Paradigm Tactical Products to be Largest Distributor of Metal/Radiation Detection Wands in United States 3Origin of root offshoots revealed 2Origin of root offshoots revealed 3Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia 2
... Choice Microsphere/Microarray Stabilizer is a is a ... This product is an aqueous solution ... buffer (phosphate buffered saline), pH 6.6 - ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
... F1 antigen, Monoclonal Antibody, Unconjugated ... Use at an assay dependent dilution. ... dilution. WB: Use at an assay ... kDa. Not tested in other applications. ...
... formulated for mounting tissue specimens, cell smears, ... immunohistochemical methods for viewing by light microscopy. ... such as AEC, that are alcohol-soluble or ... when slides are cover-slipped forming a coating ...
... is formulated for covering tissue sections and cell preparations immunohistochemically ... products. , ... Application: Vision ... AEC that require an aqueous mounting medium, or those that ...
Biology Products: